Compare CFG & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | WAT |
|---|---|---|
| Founded | 1828 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 22.5B |
| IPO Year | 2014 | 1995 |
| Metric | CFG | WAT |
|---|---|---|
| Price | $65.25 | $376.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 17 |
| Target Price | $65.05 | ★ $395.00 |
| AVG Volume (30 Days) | ★ 5.5M | 503.3K |
| Earning Date | 01-21-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 27.39 | 3.82 |
| EPS | 3.86 | ★ 10.88 |
| Revenue | ★ $7,639,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | $19.71 | $7.96 |
| Revenue Next Year | $7.81 | $6.32 |
| P/E Ratio | ★ $16.80 | $34.88 |
| Revenue Growth | ★ 7.26 | 6.90 |
| 52 Week Low | $32.60 | $275.05 |
| 52 Week High | $65.88 | $417.10 |
| Indicator | CFG | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 43.04 |
| Support Level | $62.60 | $367.12 |
| Resistance Level | $64.13 | $401.10 |
| Average True Range (ATR) | 1.55 | 9.46 |
| MACD | 0.14 | -2.29 |
| Stochastic Oscillator | 89.96 | 30.49 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through the bank, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The company's reportable segments are; Commercial Banking, Consumer Banking, Non-Core, and Others. A majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management and investment services.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.